Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Capital Medical University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Capital Medical University
ClinicalTrials.gov Identifier:
NCT00815594
First received: December 29, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted
  Purpose

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.


Condition Intervention Phase
Bleb Vascularity
Conjunctival Scarring
Drug: bevacizumab
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Resource links provided by NLM:


Further study details as provided by Capital Medical University:

Primary Outcome Measures:
  • bleb vascular change [ Time Frame: one day, one week, one month ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: December 2008
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: bevacizumab
    0.05ml, 1.25mg
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

  • Affected eye has normal IOP
  • Not allergic with Avastin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00815594

Locations
China, Beijing
Tongren hospital
Beijing, Beijing, China, 100730
Sponsors and Collaborators
Capital Medical University
Investigators
Principal Investigator: Liu Xuan, M.D. An ophthalmologist in Tongren hospital
  More Information

No publications provided

Responsible Party: Wang NingLi, Beiing Tongren hospital
ClinicalTrials.gov Identifier: NCT00815594     History of Changes
Other Study ID Numbers: 2008TR-LX-001
Study First Received: December 29, 2008
Last Updated: December 29, 2008
Health Authority: China: Ethics Committee

Keywords provided by Capital Medical University:
bleb
vascular change
bevacizumab
trabeculectomy
Bleb vascularity associated with increased scarring activity
Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery
the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.

Additional relevant MeSH terms:
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014